Cor Vasa 2012, 54(1-2):e16-e21 | DOI: 10.1016/j.crvasa.2012.01.009

Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients

Jevgenija Vymětalová, Miloš Kubánek, Tomáš Gazdič, Jana Vrbská, Ivan Málek, Josef Kautzner
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika

Keywords: Cytomegalovirus; Heart transplantation; Infection; Prophylaxis; Rejection; Valganciclovir

Received: December 7, 2011; Revised: January 20, 2012; Accepted: January 23, 2012; Published: January 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vymětalová J, Kubánek M, Gazdič T, Vrbská J, Málek I, Kautzner J. Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients. Cor Vasa. 2012;54(1-2):e16-21. doi: 10.1016/j.crvasa.2012.01.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Society of Transplantation. Cytomegalovirus. Am J Transplant 2004;4(Suppl.10):51-8. Go to original source...
    2. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-95. Go to original source... Go to PubMed...
    3. Snydman DR, Limaye AP, Poten L, Zamora MR. State-of-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011;43:S1-17. Go to original source... Go to PubMed...
    4. Emery V. Facing the facts: the indirect effects of cytomegalovirus. Transplantation 2007;84:S7-10. Go to original source...
    5. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6. Go to original source...
    6. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003;76:1470-4. Go to original source... Go to PubMed...
    7. Richens D, Harvison A, Kaan AM, et al. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 1995;14(1, Part 1):32-8.
    8. Bristow MR, Starnes V, O'Connel JB, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326:1182-6. Go to original source... Go to PubMed...
    9. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valgancilovir vs oral ganciclovir for the prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplan 2004;4:611-20. Go to original source... Go to PubMed...
    10. Devyatko E, Zuckermann A, Ruzicka M, et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 2004;23:1277-82. Go to original source... Go to PubMed...
    11. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990;9:587-93.
    12. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009;28;461-7. Go to original source... Go to PubMed...
    13. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006;82:398-405. Go to original source... Go to PubMed...
    14. Khoury JA, Storch GA, Bohl DJ, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134-43. Go to original source... Go to PubMed...
    15. Borchers AT, Perez R, Kaysen G, Ansari AA, Gershwin ME. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999;7:75-82. Go to original source... Go to PubMed...
    16. Tuder RM, Weinberg A, Panajotopoulos N, Kalil J. Cytomegalovirus infection amplifies class I major histocompatibility complex expression on cultured human endothelial cells. J Heart Lung Transplant 1994;13:129-38.
    17. Arbustini E, Morbini P, Grasso M, et al. Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung. Molecular, immunocytochemical, and histopathologic investigations. Transplantation 1996;61:418-27. Go to original source... Go to PubMed...
    18. Kloover JS, Soots AP, Krogerus LA, et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000;69:2641-7. Go to original source... Go to PubMed...
    19. Compton T, Kurt-Jones ES, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003;77:4588-96. Go to original source... Go to PubMed...
    20. Cook CH, Bickerstaff AA, Wang JJ, et al. Disruption of murine cardiac allograft acceptance by latent cytomegalovirus. Am J Transplant 2009;9:42-53. Go to original source... Go to PubMed...
    21. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2003;4:169-77. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes